Following Cathie Wood: Continued to add over 120,000 shares of SpaceX and trimmed gene testing positions to rebalance portfolio

On Wednesday, all three major U.S. indices rose together. The S&P 500 gained 0.38% to close at 7,572.40 points; the Nasdaq saw a more notable increase, rising 0.62% to 26,269.23 points; and the Dow Jones Industrial Average posted a modest gain of 0.29%, closing at 52,658.64 points, maintaining a steady upward market trend.

On that day, Cathie Wood aggressively added positions in innovative names within the energy and space sectors, while optimizing her portfolio in the genetic testing space by cutting weaker holdings and retaining stronger ones.

Buying focus: nuclear energy, aerospace, and AI-powered autonomous driving

ARK’s Largest Buy of the Day$X-Energy (XE.US)$reaching 204,000 shares. This small modular reactor (SMR) technology leader is benefiting from the global resurgence in nuclear energy. ARK also significantly increased its position in$SpaceX (SPCX.US)$123,000 shares, reflecting strong confidence in the long-term prospects of the commercial space industry.

In the AI segment, ARK substantially increased its stake in$Kodiak AI (KDK.US)$108,000 shares; the company focuses on autonomous trucking technology and could benefit from the accelerating trend of logistics automation. Increased holdings of Chinese ADRs during the same period$Pony AI (PONY.US)$57,000 shares and$WeRide (WRD.US)$22,000 shares, reflecting recognition of China's capabilities in autonomous driving technology.

In the precision medicine space, ARK increased stakes in gene-editing pioneer$Prime Medicine (PRME.US)$55,000 shares and$Beam Therapeutics (BEAM.US)$33,000 shares, as well as proteomics company$Alamar Biosciences (ALMR.US)$29,000 shares, continuing to build positions in next-generation healthcare technologies.

Selling activity: Adjusting exposure in the genetic testing segment

Reductions were primarily concentrated in the genetic testing and biotechnology sectors, with ARK cutting$Personalis (PSNL.US)$149,000 shares,$10x Genomics (TXG.US)$100,000 shares,$Twist Bioscience (TWST.US)$71,000 shares, etc., may reflect a cautious stance toward valuation reassessment in this niche segment.

Notably, ARK reduced its holdings of$Robinhood (HOOD.US)$33,000 shares, possibly related to a rebalancing strategy within the fintech sector. It also made a minor reduction of$Deere (DE.US)$6,833 shares, likely a tactical adjustment to its position in the traditional agricultural machinery sector.

Futubull’s [Opportunities Page] now features celebrity portfolio tracking! Choose from multiple celebrity holdings, follow top investors’ moves with one click, precisely target quality stocks, and invest with greater confidence!

149K Views